|Post IPO Valuation|
|Calistoga Pharmaceuticals, 2/2011||$375M|
|Arresto BioSciences, 12/2010||$225M|
|CGI Pharmaceuticals, 6/2010||$120M|
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, they seek to improve the care of patients suffering from life-threatening diseases.
Gileadâ€™s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
There portfolio of 13 marketed products includes a number of category firsts and market leaders, including AtriplaÂ® (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) - the first single-tablet regimen for HIV infection. The companyâ€™s first product for HIV infection, VireadÂ® (tenofovir disoproxil fumarate), has also more recently been approved for the treatment of chronic hepatitis B. Chronic hepatitis B, a serious liver disease caused by the hepatitis B virus, is the leading cause of liver cancer worldwide and affects an estimated two million individuals in the United States.